CYCLOPENTA(B)NAPHTHALENE DERIVATIVES

Details for Australian Patent Application No. 2003258538 (hide)

Owner MERCK PATENT GMBH

Inventors KLASEN-MEMMER, Melanie; HECKMEIER, Michael; LIETZAU, Lars; BREMER, Matthias

Pub. Number AU-A-2003258538

PCT Number PCT/EP03/08285

PCT Pub. Number WO2004/020375

Priority 102 38 999.3 26.08.02 DE; 103 24 843.9 02.06.03 DE

Filing date 28 July 2003

Wipo publication date 19 March 2004

International Classifications

C07C 025/22 Compounds containing at least one halogen atom bound to a six-membered aromatic ring

C07C 043/225 Ethers

C09K 019/32 Liquid crystal materials - containing condensed ring systems, i.e. fused, bridged or spiro ring systems

C07C 022/08 Cyclic compounds containing halogen atoms bound to an acyclic carbon atom

C07C 025/24 Compounds containing at least one halogen atom bound to a six-membered aromatic ring

Event Publications

13 November 2003 Complete Application Filed

  Priority application(s): 102 38 999.3 26.08.02 DE; 103 24 843.9 02.06.03 DE

6 May 2004 Application Open to Public Inspection

  Published as AU-A-2003258538

19 May 2005 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(f)/See Reg. 8.3(3). Examination has not yet been requested or directed for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003258539-Improved transdermal delivery system for the administration of rotigotine

2003258537-USE OF MODULATORS OF THE SIGNAL TRANSDUCTION PATH USING THE PROTEIN KINASE FYN FOR THE TREATMENT OF TUMOROUS DISEASES